Tiyotepa - søkeresultat

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiski līdzekļi - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

USA - engelsk - NLM (National Library of Medicine)

thiotepa injection, powder, lyophilized, for solution

hikma pharmaceuticals usa inc. - thiotepa (unii: 905z5w3gkh) (thiotepa - unii:905z5w3gkh) - thiotepa 15 mg in 1.5 ml - thiotepa for injection, usp has been tried with varying results in the palliation of a wide variety of neoplastic diseases. however, the most consistent results have been seen in the following tumors: - 1.adenocarcinoma of the breast. - 2.adenocarcinoma of the ovary. - 3.for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. - 4.for the treatment of superficial papillary carcinoma of the urinary bladder. while now largely superseded by other treatments, thiotepa has been effective against other lymphomas, such as lymphosarcoma and hodgkin's disease. thiotepa is contraindicated in patients with a known hypersensitivity (allergy) to this preparation. therapy is probably contraindicated in cases of existing hepatic, renal, or bone-marrow damage. however, if the need outweighs the risk in such patients, thiotepa may be used in low dosage, and accompanied by hepatic, renal and hemopoietic function tests.